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Background: Blood pressure (BP) is a complex trait, with a heritability of 30 to 40%. Several genome wide associated
BP loci explain only a small fraction of the phenotypic variation. Family studies can provide an important tool for gene
discovery by utilizing trait and genetic transmission information among relative-pairs. We have previously described a
quantitative trait locus at chromosome 17q25.3 influencing systolic BP in American Indians of the Strong Heart Family
Study (SHFS). This locus has been reported to associate with variation in BP traits in family studies of Europeans, African
Americans and Hispanics.
Methods: To follow-up persuasive linkage findings at this locus, we performed comprehensive genotyping in
the 1-LOD unit support interval region surrounding this QTL using a multi-step strategy. We first genotyped
1,334 single nucleotide polymorphisms (SNPs) in 928 individuals from families that showed evidence of linkage
for BP. We then genotyped a second panel of 306 SNPs in all SHFS participants (N = 3,807) for genes that displayed the
strongest evidence of association in the region, and, in a third step, included additional genotyping to better cover the
genes of interest and to interrogate plausible candidate genes in the region.
Results: Three genes had multiple SNPs marginally associated with systolic BP (TBC1D16, HRNBP3 and AZI1). In BQTN
analysis, used to estimate the posterior probability that any variant in each gene had an effect on the phenotype, AZI1
showed the most prominent findings (posterior probability of 0.66). Importantly, upon correction for multiple testing,
none of our study findings could be distinguished from chance.
Conclusion: Our findings demonstrate the difficulty of follow-up studies of linkage studies for complex traits,
particularly in the context of low powered studies and rare variants underlying linkage peaks.Background
Blood pressure (BP) is a complex trait and genetic factors
account for 30 to 40% of the blood pressure variation in a
population [1]. Recent progress has been made in the
identification of common variants associated with BP and
hypertension risk in populations [2-7], with over 50 loci
for BP traits identified in genome-wide association studies
(GWAS) [2-5,8-10]. However, these findings only explain
a small fraction of the phenotypic variation attributable to
genetic effects [4]. Evidence for a role of rare variants in* Correspondence: noraf@unc.edu
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article, unless otherwise stated.BP is well documented in monogenic forms of hyperten-
sive and hypotensive syndromes [11,12].
Family studies can provide an important tool for gene/
loci discovery by utilizing trait and genetic transmission
information among relative-pairs. Several genome scans
of BP and hypertension have been published but few
overlapping regions have been identified [recently reviewed
in [1,13]]. Many of these studies failed to show genome-
wide significant linkage. Those demonstrating strong
evidence for linkage have identified quantitative trait
loci (QTLs) on chromosomes 2p [Mexican Americans [14]
and families from Sardinia [15]] ,2q [African Americans
[16] and Amish [17]], 3 [Finnish families [18]], 4p [Dutch
families [19]], 6q [European Americans [20,21], white
Europeans [22]], 7 [African Americans [23]], 17q [Europeanntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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families [26] and European Americans [27]], 20 [Hispanics
[23]] and 21 [European Americans [23]].
We have previously described a QTL-specific genotype-
by-sex interaction for systolic BP on chromosome 17q25.3
in American Indians participants of the Strong Heart
Family Study (SHFS) [28]. This is the same region identi-
fied in European Americans [24] and Hispanics [23,25] for
BP traits. This QTL became more significant when we
accounted for an interaction by sex (LOD =3.4 in women
in comparison to men). To follow-up persuasive linkage
findings at this locus, we performed comprehensive geno-
typing in the chromosome 17q region using a three-stage
strategy. We first genotyped a panel of single nucleotide
variants (SNVs) in individuals belonging to families that
showed strong evidence of linkage for systolic BP and then
genotyped a second panel of SNV in all SHFS participants
for the genes displaying the most prominent evidence
for association in the region. As a third stage we typed
additional variants in the genes of interest as well as fur-
ther characterized additional candidate genes from the
region. Finally, because our linkage findings were stron-
gest in the female only sample, we examined the associ-
ations in males and females separately. Here we report
the results from these analyses.
Methods
SHFS study design, population and phenotypes
We used data from the SHFS, a large family-based gen-
etic component of the Strong Heart Study (SHS), a
population-based study of cardiovascular disease and
its risk factors in American Indians 45 years or older
recruited from tribes in Arizona (AZ), Oklahoma (OK)
and North and South Dakota (DK). The SHFS began as
a pilot study in 1998 when ~900 members of extended
families of the SHS cohort were examined. Additional
family members were recruited from 2001 to 2003 for
a total of 3,807 individuals in 94 multigenerational
families (mean family size of 40 individuals, range 5 to
110). The SHFS protocols were approved by the Indian
Health Services (IHS) Institutional Review Board, by
Institutional Review Boards of all Institutions, and by
the Indian tribes [29,30]. All participants gave informed
consent for genetic testing. The study was conducted
according to the principles expressed in the Declaration of
Helsinki.
Baseline socio-demographic, medical history, lifestyle
and behaviors (smoking and alcohol intake) and medica-
tions were obtained through an interview using standard-
ized questionnaires. Physical exams collected data on
height, weight, systolic and diastolic BPs. Body mass index
(BMI) was estimated using height and weight (kg/m2). BP
was measured using a standard protocol across the three
recruiting centers [30]. Brachial seated BPs were measuredthree times by a trained technician using a mercury col-
umn sphygmomanometer (WA Baum Co Inc, Copiague,
NY) and size-adjusted cuffs. The average of the last two of
the three measures was used in the analyses. Hypertension
is defined by a BP of 140/90 mm Hg or higher, or use of
antihypertensive drugs [31].
Genotyping strategy, methods and quality control
The genotyping strategy is shown in Additional file 1:
Figure S1.
Stage 1: SHFS panel 1
SNVs were selected within the 1-LOD unit drop support
interval of the chromosome 17 QTL from 69,509,00 to
77,946,426 bp (genome build 35). We identified all poly-
morphic variants in HapMap CEU and JPN/HCB. We
used linkage disequilibrium (LD) metrics (r2) and minor
allele frequency (MAF) (SNVs with a MAF <0.001 in the
HapMap data were removed) to select SNVs for geno-
typing. We also included 2 variants located in miRNA. A
total of 1,536 SNVs were genotyped in 933 SHFS partici-
pants who are members of families showing evidence of
linkage for systolic BP. Of the 1,536 SNVs on chromosome
17 that were included, 1334 SNVs were heterozygous, 18
SNVs were not polymorphic, and 184 SNVs failed genotyp-
ing. Five individuals had call rates < 95% and were removed
from further analyses. Therefore, 1,334 heterozygous SNVs
in 920 individuals were available for analyses.
Stage 2: SHFS panel 2
To provide evidence of replication for the genes on
chromosome 17 that show the highest association, we
genotyped 639 of the most significant SNVs of the Panel
1 analysis in all SHFS members (n = 3,800) and included
additional SNVs in regions where we had relatively low
coverage in Panel 1 (n = 30 SNVs). We also genotyped
additional SNVs in these genes and in several other can-
didate genes in the region (23 SNVs in AZI1; 156 in
HRNB3; 52 in TBC1D16; 8 in ACTG1; 5 in UTS2R; 34
in ACE; 33 in SCL39A11), for a total of 980 SNVs.
Stage 3: SHS cohort genotyping
We genotyped 91 of the most prominent SNVs in add-
itional 3,516 SHS cohort members.
For the strategies described above, genotyping was
performed using the multiplex Golden Gate genotyping
technology from Illumina, based on allele-specific pri-
mer extension, according to the manufacturer’s protocol
(Illumina, San Diego, CA). Briefly, genomic DNA (250 ng)
was activated with biotin, hybridized to a pool of locus-
specific oligos. PCR amplified using fluorescent-labeled
primers and hybridized to the Sentrix Array Matrix, and
then fluorescence intensities were analyzed using the Illu-
mina BeadArray Reader and BeadStudio software. Cluster
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exported as text files for further use in association analysis.
Additional samples were typed in replica as controls for
genotyping and allele calling consistencies.
Existing genetic data in the SHFS
The SHFS has existing genotypic data on ~400 micro-
satellite markers [32]. MAFs were derived from pedi-
gree founders. Mendelian inconsistencies and spurious
double recombinants were detected using the SimWalk2
package [33] with the overall blanking rate for both types
of errors of less than 1%. Multipoint identity-by-descent
(IBD) sharing was estimated using Loki [34]. Pedigree
relationships were verified using the PREST package [35].
This information was used in the implementation of the
Quantitative Trait Nucleotide (QTN) analysis.
Statistical analyses
We evaluated quantitative variation in systolic BP. To
account for the use of anti-hypertensive medications, we
added a constant to treated measures of systolic BP
(10 mm Hg). Systolic BP was log-transformed due to
non-normality of the data. Models also adjusted for age,
sex, age2, and BMI and stratified by study center.
Association analysis
We implemented a single marker test for each SNV. To
evaluate the association of SNVs with BP traits among
family members, we fitted linear mixed effects models to
account for within pedigree correlations (implemented
in Genome-Wide Association analyses with Family
[GWAF]) [36]. Genotypes were tested for additive as-
sociation using a 1-df Wald test. Analyses report beta
and standard error (se) per copy number of the coded
allele. Summary results of each center were combined
using fixed effects meta-analysis. Significant p-value
thresholds were determined using a Bonferroni correc-
tion (Stage 1: 1,334 SNPs, p < 3.7 × 10−5).
Population stratification
The SHFS does not have ancestry informative markers
to adjust for population stratification. Therefore, we tested
for the evidence of population stratification for each vari-
ant using the quantitative transmission disequilibrium test
(QTDT) [37] and a test for stratification described by
Havill et al. [38], both implemented in SOLAR. To control
for spurious associations due to population stratification
and admixture, genotype scores are decomposed into
between-family and within-family components, and the
likelihood of a model in which the association parameters
of these two components are estimated is compared to
the likelihood of a model in which they are constrained
to be equal, as expected in the absence of population
stratification.Bayesian Quantitative Trait Nucleotide (BQTN) method
For genes showing the most significant associations with
systolic blood pressure, we used the BQTN to estimate
the probability that each SNV is functional [39]. The
BQTN method is designed to separate potentially func-
tional variants from neutral variants in LD with them based
on a displacement in the observed phenotype values and
it incorporates each variant one by one, evaluating the
likelihood of a model in which the trait mean varies by
genotype. SNVs having a LD r2 higher than 0.90 are
treated as in one group and only one SNV in each group
will be used in the analysis. Bayesian model averaging/
model selection was used based on additive QTN effects,
for which there are 2m possible models, where m is the
number of QTNs considered (m was restricted to ≤ 15
SNVs). The approach evaluates all such models and
utilizes Bayesian methods to estimate the posterior
probability that each SNV is functional. It then evaluates
models with all possible combinations of two variants,
three variants, and so on. Each model will also have the
effect size estimate and its standard error for each SNV
appearing in that model, the averaged effect size and
standard error for that SNV in that gene and the sum of
posterior model probabilities across all models containing
the SNV.
Results
Descriptive characteristics of individuals genotyped in
the SHFS and SHS are shown in Additional file 1: Table
S1. The panel 1 sample was comprised of individuals
from families with evidence of linkage for systolic BP
(stage 1), and Panel 2 included all participants of the
SHFS (Stage 2). Single SNV association results for Panel
1 are shown in Additional file 1: Table S2. Three genes
had multiple SNVs marginally associated with systolic
BP (TBC1D16, HRNBP3 and AZI1) and low evidence for
heterogeneity across centers (Figures 1, 2 and 3). There
was no evidence of population stratification for these
associations (p > 0.10) except for the SNP rs8070973 in
the Oklahoma sample (p = 0.03 for the stratification
test). However, the p-value for association of this SNP
with systolic BP was 0.008 using the QTDT test, which
accounts for population stratification. The pattern of LD
of these genomic regions in the three centers is shown
in Additional file 1: Figure S2. These three genes were
prioritized for further characterization in the second
genotyping panel in the entire SHFS sample. Association
findings from Panel 2 for systolic BP also pointed to the
same three genes (Additional file 1: Table S3). Table 1
shows the meta-analyses main results across centers for
systolic BP in these Panels and in the SHS cohort study.
For SNVs genotyped in both Panels, we noticed higher
effect estimates in family members selected based on the
linkage results (Panel 1) compared to the overall individuals
Figure 1 Chromosome 17 single nucleotide variant associations among linked family members (n = 920 family members; 1,334 SNVs):
HRNBP3-TBC1D16 locus.
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SHFS and SHS are shown in Additional file 1: Tables S4
and S5, respectively. Association findings for females and
males are shown in Additional file 1: Tables S6 and S7.
We used the BQTN method to estimate the posterior
probability that any variant in each gene had an effect
on the phenotype in Panel 1 which showed stronger asso-
ciation estimates (Table 3). This analysis showed marginal
posterior probability for a SNV on the AZI1 gene (>60%)Figure 2 Chromosome 17 single nucleotide variant associations amon
AZI1 locus.but no strong probabilities of effects for any of the typed
SNVs. BQTN analyses of Panel 2 SNVs did not reveal any
SNV with a notable posterior probability of effect (data
not shown).
Discussion
To follow up persuasive evidence of genome wide link-
age findings for systolic BP in American Indians, we per-
formed a comprehensive fine mapping of a chromosomeg linked family members (n = 920 family members; 1,334 SNVs):
Figure 3 Chromosome 17 single nucleotide variant associations among linked family members (n = 920 family members; 1,334 SNVs):
RNF157 locus.
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heterogeneity in association analyses, with suggestive
(nominal) associations of SNVs in three genes (TBC1D16,
HRNBP3 and AZI1) in single test analyses. Importantly,
upon Bonferroni correction for multiple testing, none
of these study findings can be distinguished from
chance. Using the BQTN method to estimate the pos-
terior probability that any SNV in each gene had an
effect on the systolic BP, the AZI1 rs12939525 SNV
showed the most prominent findings (posterior prob-
ability of 0.66).
The three genes that displayed the strongest evidence
for association with blood pressure have not been previ-
ously associated with blood pressure traits. AZI1 encodes
the 5-azacytidine induced 1 protein. This cell cycle protein
is thought to play a role in spermatogenesis, through
the recruitment of mitotic centrosome proteins and
complexes. HRNBP3 encodes hexaribonucleotide bindingTable 1 Results (p-value) of association analyses of single nuc
Gene SNV SHFS linked families
(n=920)
HRNBP3 rs11651204 8.7 × 10–4
HRNBP3 rs8070973 2.4 × 10–3
TBC1D16 rs1115834 8.8 × 10–3
TBC1D16 rs2362384 1.6 × 10−3
AZI1 rs12939525 6.1 × 10−3
Analyses of natural log-transformed systolic BP, adjusted for age, age2, sex, age*sex
single nucleotide variant, SHFS Strong Heart Family Study, SHS Strong Heart Study.protein 3. This complex gene encodes 10 different
mRNAs, 9 alternatively spliced variants and 1 unspliced
form. Functionally, the gene has been proposed to partici-
pate in mRNA processing/splicing and functions to bind
RNA and to localize in the extracellular space, cytoplasm,
and nucleus [40-42]. TBC1D16 encodes the protein TBC1
Domain Family, Member 16, which is up-regulated in
melanoma. Recent studies have shown that TBC1D16
enhances the intrinsic rate of GTP hydrolysis by Rab4A, a
master regulator of receptor recycling from endocytic
compartments to the plasma membrane [43].
While a plausible story for a gene-phenotype relation-
ship is often easy to make, especially given the general cell
cycle functions of the identified candidate circulating pro-
teins implicated here, no single gene nor SNV displayed a
Bonferroni corrected p-value supporting statistical sig-
nificance, suggesting that perhaps multiple variants of
small individual effect account for the linkage evidenceleotide variants with systolic blood pressure
SHFS without linked families
(n=2,880)
SHS cohort
(n=3,516)
0.52 −
7.8 × 10–3 0.71
0.11 0.48
0.50 0.76
0.96 0.13
and BMI. Meta-analyses using center-specific estimates. Abbreviations: SNV
Table 2 Comparison of effect size and p-values from analyses using individuals selected from families showing linkage
for SBP (Panel 1) and analyses using the entire SHFS (Panel 2)
Panel 1 Panel 2
Gene SNV Effect
allele
Other
allele
Frequency
effect allele
Beta SE P-value P-value
heterogeneity
Beta SE P-value
TBC1D16 rs2362384 G A 0.05 0.0469 0.0149 0.002 0.6897 0.0065 0.0076 0.39
AZI1 rs12939525 G A 0.17 −0.0231 0.0084 0.006 0.3663 −0.0063 0.0040 0.12
AZI1 rs9896850 G A 0.82 0.0227 0.0083 0.006 0.336 0.0065 0.0040 0.11
TBC1D16 rs1115834 G A 0.86 −0.0223 0.0085 0.009 0.3448 0.0005 0.0042 0.91
HRNBP3 rs11656673 G A 0.86 −0.0239 0.0093 0.01 0.9068 −0.0082 0.0052 0.12
AZI1 rs9913021 G A 0.17 −0.0204 0.0083 0.01 0.5889 −0.0062 0.0040 0.12
AZI1 rs9789009 G A 0.11 −0.0248 0.0103 0.02 0.2532 −0.0134 0.0051 0.009
BRAP rs11065987 G A 0.18 −0.0228 0.0095 0.02 0.266 −0.0056 0.0046 0.22
UTS2R rs11658052 G A 0.91 0.0232 0.0099 0.02 0.3044 0.0037 0.0044 0.39
HRNBP3 rs11651204 G A 0.40 −0.0133 0.0057 0.02 0.00073 −0.004 0.003 0.18
LOC344371 rs6711736 G A 0.77 −0.0151 0.0067 0.02 0.5462 −0.0012 0.0033 0.72
LOC344371 rs9308945 G A 0.23 0.0151 0.0067 0.02 0.5462 0.001 0.0033 0.77
HRNBP3 rs1563448 G A 0.89 −0.0244 0.0113 0.03 0.4723 −0.0106 0.0063 0.09
ATP2B1 rs2681472 G A 0.08 −0.0254 0.0119 0.03 0.2504 −0.0174 0.0062 0.005
ATP2B1 rs17249754 G A 0.92 0.0253 0.0118 0.03 0.2626 0.0177 0.0062 0.004
ATP2B1 rs2681492 G A 0.08 −0.0252 0.0118 0.03 0.263 −0.0172 0.0062 0.005
HRNBP3 rs4789976 G A 0.84 0.0177 0.0083 0.03 0.9945 0.0071 0.0039 0.07
LOC344371 rs6729869 T A 0.76 −0.0143 0.0067 0.03 0.5041 −0.0007 0.0033 0.84
HRNBP3 rs12937212 G A 0.84 0.0176 0.0083 0.03 0.995 0.0068 0.0039 0.08
HRNBP3 rs12940295 C A 0.16 −0.0182 0.0088 0.04 0.8109 −0.01 0.0043 0.02
SLC39A11 rs2567494 C A 0.59 0.0121 0.0059 0.04 0.9385 −0.0012 0.003 0.69
HRNBP3 rs866414 C A 0.81 0.0149 0.0075 0.05 0.3581 0.0014 0.0037 0.71
SLC39A11 rs7210946 G A 0.53 −0.0116 0.0059 0.05 0.9928 0.0023 0.003 0.44
HRNBP3 rs10445220 C A 0.73 0.013 0.0066 0.05 0.1092 0.0043 0.0034 0.20
SNV, single nucleotide polymorphism; het, heterogeneity; SE, standard error.
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rather standard when viewed in the context of the many
previous fine mapping studies of complex traits like
blood pressure, where there has been an inherent failure
to identify a single variant that accounts for a linkageTable 3 Results from BQTN analyses for the panel 1 single nu
systolic blood pressure
Gene SNV Average SE
AZI1 rs12939525 −0.0165 0.0137
HRNBP3 rs8070973 −0.0099 0.0095
TBC1D16 rs1115834 0.0055 0.0110
TBC1D16 rs2362384 0.0290 0.0272
SLC38A10 rs7214678 −0.0146 0.0140
RNF157 rs12950642 0.0150 0.0102
RNF157 rs881502 −0.0193 0.0121
RPTOR rs9899051 0.0098 0.0095
SNV, single nucleotide variant; SE, standard error; N, number.peak [44,45]. Reasons for such failures include locus
heterogeneity as hypothesized here, lack of statistical
power, population stratification, as well as a lack of con-
sideration of rare variants, in particular variants with
MAF < 0.01.cleotide variants with the highest associations with
Posterior probability N SNVs eligible N SNVs BQTN
0.66 8 4
0.59 79 15
0.23 12 10
0.59 12 10
0.56 15 8
0.77 20 8
0.77 20 8
0.58 94 15
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definitively identifying the exact set of causal genes and
variants, particularly as they likely are low frequency or
rare, even in this population. Novel methods are needed
to map rare genes in the context of low power. These
findings support the hypothesis that there are likely
multiple underlying genes and/or variants and that
those segregating in these pedigrees may be specific to
families and not easily identified in studies of unrelated
individuals. Further interrogation of these regions with
sequencing to detect rare variants is warranted.
We observed differences in the patterns of SNV -BP
association by sex-strata but the findings were difficult
to differentiate from chance (Additional file 1: Tables S6
and S7). This is relevant because our initial linkage peak
displayed evidence of sex-specific effects [28].
Conclusions
Our results illustrate the challenges of gene discovery
using association analyses in the presence of locus and
allelic heterogeneity, which may have implications for
the study of complex traits across ancestries. American
Indian population-specific variants and low frequency/
rare variants not included in the HapMap were not
evaluated in this study, and could account for some of
the non-significant findings. The 1000 genome project
data was not available at the time of SNV selection;
however the American Indian gene pool is not captured
very well by the 1000 genome data. Sequencing of this
region could provide further information on functional
SNVs at this locus. Our results also suggest that a single
genetic variant is not likely to be the cause of the linkage
signal on 17q for blood pressure, which represents a major
challenge for variant discovery with association analysis as
power to detect effects becomes much diminished.
Additional file
Additional file 1: Genotyping strategy for fine mapping of the
chromosome 17 locus using family (SHFS) and cohort (SHS) data.
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